Shandong Weigao completes share repurchase, impacting issued and treasury balances

Shandong Weigao Group Medical Polymer Company Limited (HKEX:1066) reported a repurchase of 677,200 H shares on September 2, 2025. These shares, bought on the Exchange at prices ranging from HK$5.7 to HK$5.82, resulted in an aggregate cost of HK$3,915,968.

Following this transaction, the company's issued shares (excluding treasury shares) decreased to 4,510,306,724, while its treasury shares increased to 12,025,600. The total number of issued shares remains 4,522,332,324. All repurchased shares will be held as treasury shares.

The repurchase was conducted under a mandate granted on May 27, 2025, which authorized the company to repurchase up to 451,560,392 shares. To date, 5,377,200 shares have been repurchased under this mandate. A moratorium period for new share issues or treasury share sales is in effect until October 2, 2025.